Half Yearly Results Results Snapshot
Figures in Cr
Standalone Half Yearly Results
Sep'25
Sep'24
Sep'23
Sep'22
Sep'21
Sep'20
Sep'19
Half Yearly Analysis Highlights
Net Sales
Growth in half year ended Sep 2025 is 36.44% vs 31.16% in Sep 2024
Standalone Net Profit
Growth in half year ended Sep 2025 is 313.10% vs -74.92% in Sep 2024
Operating Profit (PBDIT) excl Other Income
Growth in half year ended Sep 2025 is 72.49% vs -24.49% in Sep 2024
Interest
Growth in half year ended Sep 2025 is 208.89% vs -30.77% in Sep 2024
Operating Profit Margin (Excl OI)
Growth in half year ended Sep 2025 has improved from Sep 2024
Compare Half Yearly Results Of Astrazeneca Phar With
Figures in Cr
Standalone Half Yearly Results
Change(INR)
Change(%)
Net Sales
1,085.40
1,245.39
-159.99
-12.85%
Other Operating Income
0.00
0.00
0.00
Total Operating income
1,085.40
1,245.39
-159.99
-12.85%
Raw Material Cost
9.49
158.69
-149.20
-94.02%
Purchase of Finished goods
849.99
345.55
504.44
145.98%
(Increase) / Decrease In Stocks
-239.58
-65.06
-174.52
-268.24%
Employee Cost
124.90
190.49
-65.59
-34.43%
Power Cost
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
Selling and Distribution Expenses
50.03
0.00
50.03
Other Expenses
134.28
175.77
-41.49
-23.60%
Total Expenditure (Excl Depreciation)
929.11
805.44
123.67
15.35%
Operating Profit (PBDIT) excl Other Income
156.29
439.95
-283.66
-64.48%
Other Income
17.41
109.02
-91.61
-84.03%
Operating Profit (PBDIT)
173.70
548.97
-375.27
-68.36%
Interest
1.39
5.38
-3.99
-74.16%
Exceptional Items
-5.65
0.00
-5.65
Gross Profit (PBDT)
166.66
543.59
-376.93
-69.34%
Depreciation
19.14
28.69
-9.55
-33.29%
Profit Before Tax
147.52
514.90
-367.38
-71.35%
Tax
37.47
134.13
-96.66
-72.06%
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
110.05
380.77
-270.72
-71.10%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
110.05
380.77
-270.72
-71.10%
Equity Capital
5.00
45.75
-40.75
-89.07%
Face Value
2.00
10.00
0.00
Reserves
0.00
0.00
0.00
Earnings per share (EPS)
44.02
83.23
-39.21
-47.11%
Diluted Earnings per share
44.02
83.23
-39.21
-47.11%
Operating Profit Margin (Excl OI)
14.40%
35.33%
0.00
-20.93%
Gross Profit Margin
15.35%
43.65%
0.00
-28.30%
PAT Margin
10.14%
30.57%
0.00
-20.43%
Public Share Holdings (%)
0.00%
0.00%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0.00%
0.00
0.00%
Half Yearly - Net Sales
Net Sales 1,085.40 Cr
in Sep 2025Figures in Cr
Growth in half year ended Sep 2025 is 36.44% vs 31.16% in Sep 2024
Half Yearly - Standalone Net Profit
Standalone Net Profit 110.05 Cr
in Sep 2025Figures in Cr
Growth in half year ended Sep 2025 is 313.10% vs -74.92% in Sep 2024
Half Yearly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 156.29 Cr
in Sep 2025Figures in Cr
Growth in half year ended Sep 2025 is 72.49% vs -24.49% in Sep 2024
Half Yearly - Interest
Interest 1.39 Cr
in Sep 2025Figures in Cr
Growth in half year ended Sep 2025 is 208.89% vs -30.77% in Sep 2024
Half Yearly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 14.40%
in Sep 2025Figures in %
Growth in half year ended Sep 2025 has improved from Sep 2024
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
